# Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

> **NCT03010436** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Jewish Health** · enrollment: 10 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Benralizumab

## Key facts

- **NCT ID:** NCT03010436
- **Lead sponsor:** National Jewish Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-04-15
- **Primary completion:** 2019-07-25
- **Final completion:** 2021-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03010436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03010436, "Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03010436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*